C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.38 AUD 0.73% Market Closed
Market Cap: 153.4m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
PP&E Net
AU$10.4m
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
42%
R
Respiri Ltd
ASX:RSH
PP&E Net
AU$117k
CAGR 3-Years
-10%
CAGR 5-Years
65%
CAGR 10-Years
2%
ImpediMed Ltd
ASX:IPD
PP&E Net
AU$1.4m
CAGR 3-Years
12%
CAGR 5-Years
50%
CAGR 10-Years
22%
Cochlear Ltd
ASX:COH
PP&E Net
AU$517.2m
CAGR 3-Years
6%
CAGR 5-Years
25%
CAGR 10-Years
21%
Optiscan Imaging Ltd
ASX:OIL
PP&E Net
AU$407.3k
CAGR 3-Years
-16%
CAGR 5-Years
12%
CAGR 10-Years
35%
EMvision Medical Devices Ltd
ASX:EMV
PP&E Net
AU$523.1k
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
153.4m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.01 AUD
Undervaluation 31%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's PP&E Net?
PP&E Net
10.4m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's PP&E Net amounts to 10.4m AUD.

What is Cyclopharm Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
42%

Over the last year, the PP&E Net growth was 66%. The average annual PP&E Net growth rates for Cyclopharm Ltd have been 22% over the past three years , 9% over the past five years , and 42% over the past ten years .

Back to Top